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Abstract
Backgrounds: Urologists use biopsy Gleason scores for patient counseling, prognosis prediction, and decision
making. The accuracy of Gleason grading is very important. However, the variability of Gleason grading between
general pathologists cannot be overlooked. Here we evaluate the discrepancy in the Gleason grading between
2 urologic pathologists and general pathologists as well as improvement in the accuracy of Gleason grading by
general pathologists as a result of review by urologic pathologists.
Methods: The subjects enrolled in the study were 755 patients who underwent prostate needle biopsy at
affiliate hospitals of Nara Medical University over a period of 2 years. The biopsy samples were diagnosed by
general pathologists. All biopsy samples were sent to Nara Medical University where they were diagnosed by 2
urologic pathologists. The results were then returned to the general pathologists. We compared the diagnostic
accuracy of the general pathologists with that of the urologic pathologists for the parameters of no malignancy,
atypical small acinar proliferation, high grade prostatic intraepithelial neoplasia and Gleason score (6, 3 + 4, 4 + 3
and 8–10). We then evaluated the concordance rate between the general and urologic pathologists for each of
four consecutive 6-month periods.
Results: The overall concordance rate of urologic pathologists and general pathologists in the first, second, third and
last 6-month periods was 71.8 % (140/198), 79.8 % (168/225), 89.7 % (166/185) and 89.9 % (133/148), respectively. The
concordance rate of the Gleason score between urologic pathologists and general pathologists in the first, second,
third and last 6-month periods was 47.5 %(38/80), 62.6 %(57/91),76.9 %(50/65) and 78.7 %(48/61), respectively, and the
kappa value was 0.55, 0.68, 0.81 and 0.84, respectively. The concordance rate improved significantly over the course of
each period (P = 0.04).
Conclusion: The concordance rate of the Gleason grading between the general pathologists and the urologic
pathologists was 47.5 %. However, improvement of the concordance rate as a result of review by the urological
pathologist could be seen.
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Backgrounds
Gleason et al [1] introduced the Gleason grading system
for prostate cancer in 1966 and it was modified in 1974
[2] and 1977 [3]. Gleason grading is now accepted as the
international standard for pathological grading in prostate
cancer. In Japan, Gleason grading was introduced for clin-
ical and pathological studies of prostate cancer in 2001;
since then, it has been the standard for the pathological
classification of prostate cancer [4]. Previously reported
studies demonstrated the ability of the Gleason grading
system to serve as a predictor of the final pathological
stage and prognosis [5–7]. Generally, urologists use biopsy
Gleason scores (GS) for patient counseling, prognosis pre-
diction, and decision making. It goes without saying that
the accuracy of Gleason grading is very important; how-
ever, several studies have described interobserver variabil-
ities [8, 9]. The variability of Gleason grading between
general pathologists cannot be overlooked [8, 10]. To
improve these variabilities, the International Society of
Urological Pathology (ISUP) convenced a consensus con-
ference on the Gleason grading of Prostatic carcinoma at
2005 [11]. The 2005 ISUP modified Gleason system is
considered as the currently accepted version of Gleason
grading [12, 13].
In this study, we evaluated discrepancies in Gleason
grading between urological pathologists and general pa-
thologists. We also sought to evaluate the impact of
Gleason grading by general pathologists.
Methods
Between April 2006 and March 2008, we enrolled 755 pa-
tients who underwent prostate needle biopsy at 2 hospitals
affiliated to the Nara Medical University. Approval for the
study was obtained from the Nara Medical University
Hospital Institutional Review Board. We obtained written
informed consent from each enrolled patient before bi-
opsy. Prostate-specific antigen (PSA) levels were deter-
mined using the PSA age-specific reference range
according to Ito et al. [14] The cutoff value was 3.1 ng/mL
in patients aged <65 years, 3.6 ng/mL in those aged 65–70
years, and 4.1 ng/mL in those aged ≥70 years. Biopsy was
performed under transrectal ultrasonography while adjust-
ing the number (6–12 cores) on the basis of the prostate
volume and age (Table 1) [14, 15]. All general pathologists
in both affiliated hospitals evaluated the biopsy samples.
All biopsy samples were subsequently sent to Nara
Medical University, where a urological pathological
diagnosis was made by 2 experts in prostate cancer
diagnosis who were blinded to the general pathologists’
evaluations. Each slide was diagnosed by 2 urological
pathologists. When discrepancy between urological pa-
thologists, they discussed with the case and determined
the final diagnosis. The results were then returned to
the general pathologists who reviewed the results given
by the urological pathologist. The results were only de-
scribed about GS, high grade prostatic intraepithelial
neoplasia (HGPIN), atypical small acinar proliferation
(ASAP), prostatitis, hypertrophy, or no malignancy
(NM), and portion of cancer in each core. This proced-
ure was followed for all samples. We compared the
diagnostic accuracy between general and urological pa-
thologists for the parameters of no malignancy, ASAP,
HGPIN, and GS (6, 3 + 4, 4 + 3 and 8–10) at the worst
GS for each patient. We then evaluated the concord-
ance rate between general and urological pathologists
for each 6-month period.
We used the Kruskal–Wallis test or chi-square test to
estimate the distribution of each parameter in each term.
The concordance was measured on the basis of the per-
centage of concordance and Cohen’s Kappa. Kappa
values of 0.00–0.20, 0.21–0.40, 0.41–0.60, 0.61–0.80, and
0.81–1.00 represented slight, fair, moderate, substantial,
and almost perfect concordance, respectively. These stat-
istical analyses were performed using SPSS®, version 19
(SPSS Inc., Chicago, IL). Improvement of concordance
over the course of each period was estimated by the chi-
square test for trend using Graph Pad Prism®, version
5.01 (Graph Pad Software, San Diego, CA). A p-value of
<0.05 was considered to be significant.
Results
Table 2 shows patient characteristics for each 6-month
period. No significant dispersion was noted for age, PSA
level, the number of biopsy cores, or GS between the 4
groups using the Kruskal–Wallis test or the chi-square
test.
In the first period, the overall concordance rate of uro-
logical pathologists and general pathologists was 71.8 %
(140/198 samples; Table 3). The urological pathologists
diagnosed NM in 103 samples, ASAP in 4 samples,
HGPIN in 11 patients, and prostate cancer in 80 sam-
ples. For 99 of 103 samples (96.1 %) diagnosed with NM,
1 of 4 samples (25.0 %) diagnosed with ASAP and 9 of
11 samples (81.8 %) with HGPIN, the general and uro-
logical pathologists’ diagnoses were in agreement. For 38
of these 80 samples (47.5 %), the general and urological
pathologists’ GS diagnoses were in agreement and the
kappa value was 0.55. The general pathologists under-
graded 35.1 % (27/80) samples and overgraded 18.1 %
Table 1 Optimal number of biopsy cores based on patient age





<60 60-64 65-69 ≥70
0-25 12 10 8 6
25-50 12 12 10 8
50< 12 12 12 10
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(14/80) samples (Table 4). The general pathologists diag-
nosed 120 patients with NM and 5 patients with ASAP.
Nine patients of patients diagnosed with NM and 2 of
patients with ASAP by general pathologists were diag-
nosed with prostate cancer by urological pathologists.
In the second period, the overall concordance rate of
urological and general pathologists was 79.8 % (168/225
samples; Table 5). The urological pathologists diagnosed
NM in 126 samples, ASAP in 2 samples, HGPIN in 6
patients, and prostate cancer in 91 samples. For 118 of
126 samples (93.7 %) diagnosed with NM, 2 of 2 samples
(100 %) diagnosed with ASAP and 1 of 6 samples
(16.7 %) with HGPIN, the general and urological pathol-
ogists’ diagnoses were in agreement. For 57 of these 91
samples (62.6 %), the general and urological pathologists’
GS diagnoses were in agreement and the kappa value
was 0.68. General pathologists undergraded 23.1 %
(21/91) samples and overgraded 14.3 % (13/91) samples
(Table 4). The general pathologists diagnosed 125 pa-
tients with NM and 13 patients with ASAP. Two
patients of patients diagnosed with NM and 4 of patients
with ASAP were diagnosed with prostate cancer by uro-
logical pathologists.
In the third period, the overall concordance rate of uro-
logical and general pathologists was 89.7 % (166/185;
Table 6). The urological pathologists diagnosed NM in
115 samples, ASAP in 1 sample, HGPIN in 2 patients, and
prostate cancer in 65 samples. For 115 of 115 samples
(100 %) diagnosed with NM, 1 of 1 sample (100 %) diag-
nosed with ASAP and 0 of 2 samples (0 %) with HGPIN,
the general and urological pathologists’ diagnoses were in
agreement. For 50 out of these 65 samples (76.9 %), the
general and urological pathologists’ GS diagnoses were in
agreement and the kappa value was 0.81. General patholo-
gists undergraded 11.9 % (8/65) samples and overgraded
14.1 % (9/65) samples (Table 4). The general pathologists
diagnosed 117 patients with NM and 2 patients with
ASAP. No patient of patients diagnosed with NM and 1 of
patients with ASAP were diagnosed with prostate cancer
by urological pathologists.












Age (median: yrs) 71 (41–90) 71 (46–94) 72 (41–85) 71 (46–91) 71 (44–90) 0.61a
PSA (median: ng/mL) 7.6 (0.3-5490) 7.6 (0.3–475) 7.6 (0.58–196) 7.2 (0.57–5490) 7.7 (1.0–864) 0.52a
No. of cores (median) 10 (6–12) 10 (6–12) 10 (6–12) 10 (6–12) 10 (6–12) 0.08a
GS 6 (%) 14.6 (n = 110) 17.2 (n = 34) 13.3 (n = 30) 11.9 (n = 22) 16.2 (n = 24) 0.51b
GS 3 + 4 (%) 11.1 (n = 84) 9.1 (n = 18) 12.0 (n = 27) 11.4 (n = 27) 8.1 (n = 12) 0.13b
GS 4 + 3 (%) 8.1 (n = 61) 5.6 (n = 11) 8.9 (n = 20) 7.0 (n = 13) 11.5 (n = 17) 0.23b
GS 8–10 % 6.6 (n = 50) 8.6 (n = 17) 6.2 (n = 14) 5.9 (n = 11) 5.4 (n = 8) 0.64b
PSA Prostate specific antigen, GS Gleason score
aKruskal-wallis test. bchi-square test
Table 3 Concordance of the diagnosis of a needle biopsy between urological and general pathologists (Apr./06- Sep./06)
General pathologist diagnosis Urological pathologist diagnosis
NM ASAP HGPIN 5 6 3 + 4 4 + 3 8–10 Overall
NM 99 3 9 0 9 0 0 0
ASAP 2 1 0 0 2 0 0 0
HGPIN 1 0 2 0 0 0 0 0
5 0 0 0 0 2 0 0 0
6 1 0 0 0 19 10 0 1
3 + 4 0 0 0 0 1 4 1 2
4 + 3 0 0 0 0 1 1 2 1
8–10 0 0 0 0 0 3 8 13
103 4 11 0 34 18 11 17 197
% Exact Concordance 96.1 25.0 18.1 0 55.9 22.2 9.1 76.4 71.8
% Undergrading by UPD vs GPD 38.2 55.5 18.1 23.5 35.1
% Overgrading by UPD vs GPD 5.9 22.2 72.7 0 18.1
UPD urological pathologist diagnosis, GPD general pathologist diagnosis, NM No malignancy, ASAP atypical small acinar proliferation suspicious, HGPIN high grade
prostatic intraepithelial hyperplasia
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In the last period, the overall concordance rate of uro-
logical and general pathologists was 89.9 % (133/148;
Table 7). The urological pathologists diagnosed NM in
85 samples, ASAP in 1 sample, HGPIN in 1 sample, and
prostate cancer in 61 samples. For 84 of 85 samples
(98.8 %) diagnosed with NM, 1 of 1 sample (100 %) diag-
nosed with ASAP and 0 of 1 samples (0 %) with HGPIN,
the general and urological pathologists’ diagnoses were
in agreement. For 48 of these 61 samples (78.7 %), the
general and urological pathologists’ GS diagnoses were
in agreement and the kappa value was 0.84. General pa-
thologists undergraded 16.4 % (10/61) samples and over-
graded 4.9 % (3/61) samples (Table 4). The general
pathologists diagnosed 86 patients with NM and 3 pa-
tients with ASAP. One patient of patients diagnosed
with NM and 1 of patients with ASAP were diagnosed
with prostate cancer by urological pathologists.
The kappa value increased with time. The concord-
ance rate significantly improved over the course of the
study across periods (p = 0.04).
Fifty three patients were diagnosed with prostate can-
cer by urological pathologists on one positive core and
243 patients diagnosed with prostate cancer on two or
more positive cores. Discrepancy between general and
urological pathologists was found in 30 patients (56.6 %)
of 53 and 76 patients (31.3 %) of 243 (p < 0.01),
respectively.
Discussion
Biopsy GS is an important predictor of the likelihood of
various final pathological stages of radical retropubic
prostatectomy [7], and it is also a significant predictor of
biochemical recurrence in patients who undergo radical
prostatectomy [16, 17]. Biopsy GS is also associated with
biochemical failure in those who have undergone per-
manent brachytherapy [18] and external beam radiation
therapy [19]. Biopsy GS, in combination with PSA level
and clinical stage, is a very important factor in decision
making for initial therapy. However, several studies have
described interobserver variability in Gleason grading
[8, 9]. In particular, the variability in Gleason grading
between general pathologists should not be overlooked
[8, 10]. Burchardt et al. demonstrated that 29 German
pathologists who analyzed a series of tissue microarray
images showed 45.7 % concordance with biopsy GS
assigned by an expert. [20] Coard et al. reported 67 %
Table 4 Comparison of concordance of the Gleason score between urological and general pathologists in 4 periods









scoreOverall 6 3 + 4 4 + 3 8–10
Apr./06–Sep./06 (n = 80) 47.5 (38/80) 55.9 (19/34) 22.2 (4/18) 9.1 (2/11) 76.4 (13/17) 35.1 (28/80) 18.1 (14/80) 0.55
Oct./06–Mar./07 (n = 91) 62.6 (57/91) 86.7 (26/30) 66.7 (18/27) 25.0 (5/20) 57.1 (8/14) 23.1 (21/91) 14.3 (13/91) 0.68
Apr./07–Sep./07 (n = 65) 76.9 (50/65) 72.3 (16/22) 80.9 (17/21) 53.8 (7/13) 90.9 (10/11) 11.9 (8/65) 14.1 (9/65) 0.81
Oct./07–Mar./08 (n = 61) 78.7 (48/61) 87.5 (21/24) 75.0 (9/12) 70.6 (12/17) 75.0 (6/8) 16.4 (10/61) 4.9 (3/61) 0.84
UPD urological pathologist diagnosis, GPD general pathologist diagnosis, GS Gleason score
Table 5 Concordance of the diagnosis of a needle biopsy between urological and general pathologists (Oct./06–Mar./07)
General pathologist diagnosis Urological pathologist diagnosis
NM ASAP HGPIN 5 6 3 + 4 4 + 3 8-10 Overall
NM 118 0 5 0 0 0 0 2
ASAP 7 2 0 0 0 4 0 0
HGPIN 0 0 1 0 0 0 0 0
5 0 0 0 0 0 0 0 0
6 1 0 0 0 26 3 0 0
3 + 4 0 0 0 0 4 18 8 1
4 + 3 0 0 0 0 0 1 5 3
8–10 0 0 0 0 0 1 7 8
126 2 6 0 30 27 20 14 225
% Exact Concordance 93.6 100 16.7 0 86.7 66.7 25.0 57.1 79.1
% Undergrading by UPD vs GPD 0 25.9 40.0 42.9 23.1
% Overgrading by UPD vs GPD 13.3 7.4 35.0 0 14.3
UPD urological pathologist diagnosis, GPD General pathologist diagnosis, NM no malignancy, ASAP atypical small acinar proliferation suspicious, HGPIN high grade
prostatic intraepithelial hyperplasia
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overall concordance between anatomical pathologists
and an experienced pathologist for consensus on pros-
tate cancer GS [10]. In the present study, the overall
concordance between general pathologists and the uro-
logical pathologists was 47.5 % and the kappa score was
0.55 in the first 6-month period. This was not an accept-
able concordance and was similar to the results of previ-
ous studies. These discrepancies may have been caused
by (1) a sampling effect caused by tumor heterogeneity,
(2) interpretational bias, or (3) the small volume of tis-
sue for cancer biopsy [10, 21]. In the present study, pa-
tients who diagnosed with prostate cancer on one positive
core tended to be misdiagnosed compared to those who
diagnosed on two or more cores and another reason for
discordance may have been that the general pathologists
did not refer to the 2005 ISUP consensus conference on
the Gleason grading of Prostatic Carcinoma [11].
To improve this discrepancy, Mikami et al [22] used a
40-min educational lecture or a tutorial with an anatom-
ical atlas. In a lecture group, the average concordance
rates before and after the lecture were 55.7 % and
68.4 %, and the average kappa values were 0.43 and 0.67,
respectively. In the atlas group, the average concordance
rates before and after providing the atlas were 61.3 %
and 74.5 %, and the average kappa values were 0.44 and
0.68, respectively. Allsbrook et al [8] reported that con-
cordance between general pathologists and urological
pathologists improved to 77.4 % (kappa value = 0.73) by
Table 6 Concordance of the diagnosis of a needle biopsy between urological and general pathologists (Apr./07–Sep./07)
General pathologist diagnosis Urological pathologist diagnosis
NM ASAP HGPIN 5 6 3 + 4 4 + 3 8–10 Overall
NM 115 0 2 0 0 0 0 0
ASAP 0 1 0 0 1 0 0 0
HGPIN 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0 0
6 0 0 0 0 16 3 1 0
3 + 4 0 0 0 0 5 17 2 0
4 + 3 0 0 0 0 0 1 7 1
8–10 0 0 0 0 0 0 3 10
115 1 2 0 22 21 13 11 185
% Exact Concordance 100 100 0 0 72.3 80.9 53.8 90.9 89.7
% Undergrading by UPD vs GPD 4.5 14.3 23.1 9.1 11.9
% Overgrading by UPD vs GPD 22.7 4.8 23.1 0 14.1
UPD urological pathologist diagnosis, GPD general pathologist diagnosis, NM no malignancy, ASAP atypical small acinar proliferation suspicious, HGPIN High grade
prostatic intraepithelial hyperplasia
Table 7 Concordance of the diagnosis of a needle biopsy between urological and general pathologists (Oct./07–Mar./08)
General pathologist diagnosis Urological pathologist diagnosis
NM ASAP HGPIN 5 6 3 + 4 4 + 3 8–10 Overall
NM 84 0 1 0 1 0 0 0
ASAP 1 1 0 0 1 0 0 0
HGPIN 0 0 0 0 0 0 0 0
5 0 0 0 0 0 0 0 0
6 0 0 0 0 21 3 0 0
3 + 4 0 0 0 0 1 9 3 0
4 + 3 0 0 0 0 0 0 12 2
8–10 0 0 0 0 0 0 2 6
85 1 1 0 24 12 17 8 148
% Exact concordance 98.8 100 0 0 87.5 75.0 70.6 75.0 89.9
% Undergrading by UPD vs GPD 8.3 25.0 17.6 25.0 16.4
% Overgrading by UPD vs GPD 4.2 0 11.8 0 4.9
UPD Urological pathologist diagnosis, GPD General pathologist diagnosis, NM No malignancy, ASAP atypical small acinar proliferation suspicious, HGPIN High grade
prostatic intraepithelial hyperplasia
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web-based virtual microscopy. In Egevad’s study, the
proportion of correct GS improved from 70.5 % to
86.6 % after a teaching set of 40 images illustrating GS
was distributed among 85 pathologists [23]. The present
study demonstrated an improvement in the accuracy of
general pathologists’ GS after review by 2 urological
pathologist. The rate of agreement and the kappa value
increased with the period and improved from an initial
47.5 % (kappa score = 0.55) to a final 80.3 % (kappa
value = 0.84). Furthermore in the third period, the rate
of concordance was high and the high rate continued in
the last period. So the appropriate time of this method
for improving GS may need one year by our way.
It is well known that general pathologists tend to
underestimate GS [8, 10, 20, 24]. Coard et al. reported
that anatomical pathologists undergraded 25.6 % of all
biopsy specimens and overgraded 6.7 % [10], whereas
Burchardt et al. reported that the rates of undergrading
and overgrading were 38.9 % and 15.4 %, respectively
[20]. Similar to our reports, Barqawi et al. evaluated def-
ference between outside pathologists and their institu-
tion pathologists and Gleason undergrading occurred in
46 % outside and 38 % their institution diagnosis with
respect to radical prostatectomy specimens [24]. The
corresponding values in the first period in the present
study were 35.1 % and 18.1 %, respectively, showing that
general pathologists tended to undergrade as in other re-
ports. Undergrading was particularly common for tu-
mors with a GS of 6 and 3 + 4 in our study. Allsbrook
et al. found 47 % undergrading of tumors with GS 5–6,
and 43 % undergrading of tumors with GS 7 [8]. In the
present study, the undergrading of GS in 7 samples most
probably resulted from mistaking Gleason pattern 4 for
pattern 3, and the undergrading of GS in 6 tumors most
probably resulted from mistaking pattern 3 for pattern 2.
This is in accordance with the studies of Allsbrook et al.
[8], Burchardt et al. [20], and Mikami et al. [22] Thus,
there is a tendency for general pathologists to underesti-
mate GS, especially in Gleason patterns 3 and 4.
However, the rate of undergrading decreased to 16.4 %
in the last period after general pathologists had the ex-
perienced of review by the urological pathologists in the
present study. Mikami et al. reported an improvement in
the rate of undergrading from 36.3 % to 14.2 % after a
lecture [22]. Egevad reported improvement of under-
grading by the use of reference images [23]. It shows
that the tendency for general pathologists to undergrade
can improve when they study GS patterns using any of
the common methods. Particular improvement in under-
grading among general pathologists can be expected by
preventing mistakes in identifying Gleason pattern 3 for
pattern 2 and pattern 4 for pattern 3.
20 patients who diagnosed with NM and ASAP by
general urologists were diagnosed with prostate cancer
by urological patients. This discrepancy could be fatal. This
discrepancy improved with time, 17/263 (6.5 %) in first and
second period to 3/208 (1.4 %) in third and fourth period in
the presents study (p = 0.01, chi-square test). Furthermore
in 14 cases (70 %) the positive core was one. These result
showed the discrepancy was caused by small cancer volume
and interpretative error.
A limitation of this study was the inability to isolate the
general pathologists from other educational sources associ-
ated with Gleason scoring over a period of 2 years. Therefore,
any improvement seen may not necessarily be a direct result
of the experience of the review by the urological pathologists.
Conclusion
The concordance rate of GS between the urological and
general pathologists was initially low (47.5 %), but fol-
lowing the expert reviews there was a significantly im-
provement in concordance rate over time.
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